16:29 , Sep 21, 2018 |  BC Week In Review  |  Company News

Novo's R&D restructuring adds to innovation push

Four new R&D centers fueled by a dedicated business development unit and increased investment in machine learning and AI form the basis of an R&D restructuring announced by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) on...
20:53 , Sep 18, 2018 |  BC Extra  |  Company News

Novo's R&D restructuring adds to innovation push

Four new R&D centers fueled by a dedicated business development unit and increased investment in machine learning and AI form the basis of an R&D restructuring announced by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) on...
19:43 , May 18, 2018 |  BC Week In Review  |  Company News

Novo Nordisk in stem cell therapy deals

Lund University (Lund, Sweden) and Duke-NUS Medical School (Singapore) each partnered with Novo Nordisk A/S (NYSE:NVO; CSE:NOVO B) and granted the company rights to develop stem cell-based therapies. The therapies are based on Biolaminins from...
23:42 , Sep 14, 2017 |  BC Extra  |  Company News

Management tracks: SymCel, Taro, Akcea

SymCel Sverige AB (Spanga, Sweden) named Jesper Ericsson CEO. He was director of marketing and sales at BioLamina AB (Stockholm, Sweden). SymCel offers a cell-based assay for real-time monitoring of cell metabolism. Prescription and OTC...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

BioLamina, Roche deal

Roche partnered with BioLamina to develop laminin-based cell culture matrices for applications including stem cell research. Roche will provide R&D funding and scientific expertise to BioLamina. The partners declined to disclose financial details. Laminins are...
07:00 , Oct 31, 2011 |  BioCentury  |  Politics, Policy & Law

Stem cell workaround in EU

The sky isn't falling for embryonic stem cell technologies in Europe. Despite a broad ruling by the European Court of Justice that products derived from embryonic stem cells cannot be patented, the scientific complexity of...
07:00 , Jun 10, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Long-term monolayer culture protocol of human stem cells using human recombinant laminin-511 A protocol for culturing monolayers of human stem cells using laminin-511 could help...